We examined single nucleotide rs11465553 polymorphism in the interleukin-17F gene causing valine to isoleucine substitution at the position 155 in the third exon of IL17F gene in Serbian patients with psoriasis and healthy blood donors. For the first time we found rs11465553 G (valine) and A (isoleucine) allele frequency in healthy Serbian population and in psoriasis patients, but without statistically significant difference between the two groups. P soriasis vulgaris (PsV) is a common chronic infl ammatory skin disease aff ecting approximately 2-4% of the general population, with signifi cant ethnic and geographic variations. Psoriasis is characterized by cutaneous infl ammation and keratinocyte hyperproliferation that may be accompanied by severe complications, such as psoriatic arthritis (PsA), a debilitating infl ammatory joint disease (1). Based on the time of onset, psoriasis is divided into type 1 -early onset psoriasis (disease starts before the age of 30) and type 2 -late onset psoriasis, which appears later in life (2). Type 1 psoriasis aff ects approximately 65% of psoriasis patients and it is usually associated with progressive course of the disease. Disease severity and activity is usually measured by Psoriasis Area and Severity Index (PASI) (3, 4).
this subpopulation in the initiation/maintenance of infl ammatory processes in psoriatic skin and yielding potent therapies in the treatment of PsV (5) . Induction of Th 17 response leads to release of proinfl ammatory IL17 family cytokines such as IL17A and IL17F from Th 17 and  T-cells which further infl uence keratinocyte activation (6) . IL17F induces release of proinfl ammatory and neutrophilmobilizing cytokines such as IL-6 and IL-8 (7), which enhance skin infl ammatory pathways and further development of skin lesions in psoriasis (8) . IL17F in psoriatic lesions is produced by neutrophils and mast cells (9) .
Previous studies have shown that psoriasis belongs to so-called complex genetic diseases, in which the risk of inheriting the disease appears to be determined by interaction of multiple genes. IL17F is a gene located on the short arm of the chromosome 6 (6p12) and represents an interesting area in the investigation of chronic infl ammation pathways. Some single nucleotide polymorphisms (SNPs) in IL17F, P soriasis vulgaris (PsV) is a common chronic infl ammatory skin disease aff ecting approximately 2-4% of the general population, with signifi cant ethnic and geographic variations. Psoriasis is characterized by cutaneous infl ammation and keratinocyte hyperproliferation that may be accompanied by severe complications, such as psoriatic arthritis (PsA), a debilitating infl ammatory joint disease (1) . Based on the time of onset, psoriasis is divided into type 1 -early onset psoriasis (disease starts before the age of 30) and type 2 -late onset psoriasis, which appears later in life (2) . Type 1 psoriasis aff ects approximately 65% of psoriasis patients and it is usually associated with progressive course of the disease. Disease severity and activity is usually measured by Psoriasis Area and Severity Index (PASI) (3, 4) .
Substantial evidence supports a central role of interleukin-17 (IL17) -producing T cells (Th 17) dysregulation resulting in psoriasis (1) . Th e recent development of biological drugs that target cytokines secreted by Th 17 has confi rmed the importance of such as rs763780 T/C which represents a substitution of histidine at position 161 to arginine in IL17F, are associated with ulcerous colitis, a typical Th 17 disease (10) , but also bronchial asthma, a typical Th 2 disease (7). However, association of SNPs in IL17F and PsV susceptibility is still unclear due to small number of studies and insuffi cient data. A recent study in Japan showed that rs763780 polymorphism is not associated with an increased susceptibility to PsV (11) .
Bearing in mind the important role of IL17 cytokines in psoriasis, ethnic diff erences, and the lack of clearly defi ned polymorphisms of IL17F, which may be considered biomarkers of PsV susceptibility, we investigated whether rs11465553 G/A polymorphism, causing valine to isoleucine substitution at the position 155 in the IL17F, can be used as a potential biomarker of susceptibility to PsV. 
Patients and methods

Results
Genotype frequencies were in Hardy-Weinberg equilibrium for healthy controls and patients. X 2 values were 3.15 for healthy blood donors and 0.07 for patients (<3.84 which is a threshold of signifi cance at the level of 0.05) ( Table 2 ), suggesting that a suffi cient number of subjects were analyzed in each group, and that G and A alleles were inherited in accordance with Mendel's laws. Th e results of genotyping for patients with PsV and healthy controls along with p values, odds ratios and confi dence intervals are presented in Table 3 . Th e allele frequencies and genotype distribution for rs11465553 IL17F polymorphism (Table 3) . Th e frequencies of G and A alleles in subgroups of patients with early disease onset (psoriasis type 1) and late onset (psoriasis type 2) were similar, and did not reach the level of statistical signifi cance compared to control subjects (data not shown).
When we stratifi ed rs11465553 G and A allele carriers according to disease severity measured by PASI, we found no statistical signifi cance between tested groups, although a trend toward higher percentage of A allele carriers (p=0.086) was observed in the group of patients with lower disease severity (Table 4) . (12), while in South Korean patients rs11465553 was not associated with Behçet disease, another neutrophils mediated disease (13) . Th e main limitation of our study is the limited number of patients, precluding more general conclusions. Although in our study the frequency of A alleles was twice higher in controls than in patients with psoriasis, a small total number of A alleles resulted in failure to demonstrate signifi cant diff erences in the distribution of alleles and genotypes between PsV patients and controls. A gradual decline of A allele frequency with the increase of PsV severity was also not statistically signifi cant. Similarly, although we could not demonstrate presence of A allele in any of 26 patients with PsA, the diff erence was not statistically signifi cant. However, these data may indicate that a study involving more PsV and PsA patients is warranted to demonstrate potentially protective eff ect of rs11465553 A allele in PsV and PsA.
Comparing the frequency of A allele in healthy Serbian, Saudi Arabian and South Korean population, we found that A allele is more frequent in Serbian population compared to both other populations.
Despite its limitations, our study is the fi rst study that demonstrates distribution of IL17F -a (Eppendorf AG, Hamburg, Germany), a prema preporukama proizvođača mešavine oligonukleotida. Testirani uzorci bili su u Hardy-Weinberg ravnoteži a poređenje frekvencija alela između različitih grupa obavljano je 2 testom ili Fišerovim testom tačne verovatnoće. Rezultati. Urađena je analiza polimorfi zma rs11465553. Nije ustanovljena statistički značajna razlika u frekvenciji alela kao ni u frekvenciji genotipova između pacijenata obolelih od vulgarne psorijaze i zdravih kontrolnih osoba, iako je primećeno da je frekvencija A alela bila viša kod zdravih, kontrolnih osoba u odnosu na obolele odpsorijaze.. Diskusija. Naša studija je prva studija kojim je ustanovljena distribucija G i A alela u trećem eksonu gena za IL17F kod zdravih osoba i pacijenata sa vulgarnom psorijazom u Srbiji. U poređenju sa rezultatima drugih studija u kojima je analiziran ovaj polimorfi zam, ustanovljeno je da je frekvencija A alela u zdravoj populaciji Srbije češća u odnosu na frekvenciju A alela u zdravim populacijama Koreje i Saudijske Arabije.
Polimorfi zam interleukina 17F gena-rs11465553 kod srpskih pacijenata sa psorijazom i zdravih osoba
Sažetak
Zaključak. Po prvi put je u Srbiji analiziran polimorfi zam rs11465553. Rezultati naše studije predstavljaju istovremeno i prvu publikaciju u kojoj je sa aspekta polimorfi zma pojedinačnih nukleotida, opisana distribucija alela i genotipova rs11465553 polimorfi zma u jednoj evropskoj populaciji. Odgovor na pitanje da li A alel ima protektivnu ulogu u odnosu na oboljevanje od psorijaze pružiće buduća istraživanja sprovedena na većem broju obolelih.
Ključne reči
Interleukin-17; Polimorfi zam pojedinačnih nukleotida; Psorijaza; Psorijatični artritis; Davaoci krvi; Valin; Izoleucin; Lančana reakcija polimeraze u stvarnom vremenu
